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2.075-17.734) p0.001], age [OR0.93(IC95%, 0.87-0.994) p0.032]. inhaled-beta2-
adrenérgic [OR0.101 (IC95%, 0.017-0.589) p0.021] SGRQ-Impact scale [OR1.064
(IC95%, 1.014-1.117) p0.012], SGRQ-Activity scale [OR0.96 (IC95%, 0.924-0.997)
p0.034]. CONCLUSIONS: The performed intervention improves adherence in pa-
tients with COPD.
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OBJECTIVES: To assess efficacy and safety of dornase alfa in the treatment of cystic
fibrosis (CF) in children and adults. METHODS: Systematic review of Medline, Em-
Base, CENTRAL and clinicaltrials.gov databases was conducted. The references
from relevant articles and abstracts from conferences were also examined to iden-
tify any additional studies. Each full-text article was critically appraised with use of
the Jadad Scale. Clinical practice and CF treatment procedures in Poland were
consulted with clinical experts. Placebo and treatment without dornase were iden-
tified as potential comparators. Changes in FEV1, FVC, and FEF25%-75%, exacerbation
of respiratory symptoms, body mass change, use of drugs, number of days spent at
home due to CF, hospitalizations (number and length), ambulatory visits, quality of
life, mortality rate, treatment acceptance by patient and safety were assessed and
compared based on the review results. RESULTS: Among 294 reports found, 17
publications concerning 12 randomized clinical trials were included in the analy-
sis. The meta-analysis of available data regarding changes in FEV1 after 1, 3, 6
months and 1 and 2 years showed better results with dornase therapy. The use of
dornase also improved pulmonary function measured in FVC. Exacerbations of
respiratory symptoms were less frequent (by 20% when dornase alpha was admin-
istered once daily and by 34% when administered twice daily), which resulted in
fewer hospitalizations. Patients treated with dornase required less frequent
courses of intravenous antibiotics and spent fewer days at home due to CF. Safety
analysis showed a higher risk of rash, voice alteration and pharyngitis with dor-
nase. Mortality was similar among groups. CONCLUSIONS: Dornase alfa is an ef-
fective (improves respiratory function, reduces CF symptoms, dyspnea and respi-
ratory system exacerbations) and safe therapeutic option.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a chronic respira-
tory disease characterised by a decline in lung function over time. The objectives of
this literature review were to quantify COPD burden worldwide in terms of inci-
dence, prevalence, mortality and identify trends in these data over time, in eleven
countries: Australia, Canada, France, Germany, Italy, Japan, The Netherlands,
Spain, Sweden, the UK, and the United States. Here, we focus on mortality in COPD.
METHODS: A structured literature search (January 2000-September 2011) of
PubMed, and EMBASE was conducted to identify English-language articles report-
ing prevalence, incidence and/or mortality of COPD. Of 2,838 articles identified, 299
full-text articles were reviewed, and data extracted from 133 publications.
RESULTS:Mortality data were extracted from 58 articles (numbers include 7 multi-
country studies that provide data for specific countries): Australia (n6); Canada
(n6); France (n3); Germany (n1); Italy (n2); Japan (n2); The Netherlands
(n4); Spain (n5); Sweden (n7); UK (n4); USA (n30). In Sweden and the UK,
patients with COPD were reported to have a mortality rate almost double that of the
general population, and COPD mortality was two to three times greater in females
than males in the The Netherlands, Italy and Germany. More recently, one retro-
spective US study conducted in 2000-2005, reported an increase in mortality rate in
women (54.4 to 56.0 per 100,000) but a decrease in men (83.8 to 77.3 per 100,000).
CONCLUSIONS: This is the first structured literature review to compile data on
COPD mortality. Although COPD mortality rates have increased over time, more
recently rates have declined, indicating improvements in COPD management.
However, the mortality rate in women with COPD has increased, while it has de-
creased in men. This can probably be explained by the relative differences in smok-
ing patterns between men and women.
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OBJECTIVES: Maximum sildenafil dose dispensed by the Brazilian public health-
care system for pulmonary arterial hypertension (PAH) treatment is 60 mg daily.
According to clinical practice, higher doses have been prescribed by most physi-
cians. This systematic review aims to evaluate sildenafil efficacy and safety in
doses above 60mg daily in PAH treatment. METHODS: A systematic review was
conducted in May 2011 through Cochrane Collaboration, Medline, EMBASE, and
Lilacs databases. Inclusion criteria’s considered were meta-analysis, systematic
reviews, randomized clinical trials, and observational studies using sildenafil
above 60mg for any etiology PAH on WHO/NYHA functional classes II-IV patients
over 12 years old. The exclusion criteria’s were sample size below 10. Only sildenafil
as monotherapy was considered. Outcome measures were distance walked in six
minutes (6MWD), functional classification, and satisfactory adverse events profile,
defined as similar to doses up to 60mg daily. Two independent reviewers selected
articles qualitatively rated according to Oxford Center for Evidence-Based Medicine
classification. RESULTS:Of 337 titles found, 45 articles evaluated and 16 selected (1
meta-analysis, 5 randomized trials and 10 observational studies). All but one dem-
onstrated the benefit of sildenafil higher doses in 6MWD with satisfactory safety
profile . In a 3-year follow up (SUPER 2), 46% of patients increased 6MWD and 60%
maintained or improved their functional classification with 240mg daily compared
to lower doses baseline. Two studies evaluated optimal sildenafil dose. Chockling-
man (2005) found that 100mg daily improved 6MWD (23444 vs. 377128 meters,
p0.001) and WHO/NYHA class (3.80.4 vs. 2.40.5, p0.002), from baseline. Garg
(2007) tested from 37.5mg to 300mg daily and 6MWD increased from 247.474.4 to
366.393.8 meters (p0.0001). Optimal dose appeared to be 150mg daily, with some
additional benefit by increasing up to 225mg. CONCLUSIONS: Literature review
supports that sildenafil in doses above 60mg daily is safe and may provide addi-
tional benefit to patients with PAH functional classes II-IV.
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BACKGROUND: Cystic Fibrosis (CF), the most common hereditary disease in Amer-
icans of European descent, affects 30,000 children and adults in the US. An impor-
tant measure of the effectiveness of a new medicine for CF is its ability to extend
survival past the result expected with the current standard-of-care. However, pre-
dicting what the natural median survival is for a cohort is not simple. Patient
cohorts that have lived long enough that the median survival can be directly ob-
served are not relevant to people born in the past twenty years as the standard-of-
care has advanced significantly. On the other hand, with the resulting improve-
ments in survival, post-1990 cohorts still have greater than 90% survival and it will
take several decades before the median survival can be directly observed.
OBJECTIVES: To estimate median survival for average North American patients
with CF as a function of covariates, including age, gender, weight-for-age z-score,
infection status and lung function. METHODS: A review of survival curves pub-
lished by Canadian and US CF registries yielded 19 survival curves representing
different birth cohorts. A Weibull function was fitted to the data. Using odds ratios
the average survival curve could be adjusted to accommodate cohorts with non-
average characteristics. RESULTS: A closed form equation was developed that es-
timates the survival function of cohorts with different clinical and demographic
characteristics. It predicts, on average, patients with CF born today may live past
forty years. CONCLUSIONS: The estimated survival function agreed well with his-
toric data. By translating clinical results into survival, we believe the model can aid
in evaluation of the value of new therapies. Supported by Vertex Pharmaceuticals
Incorporated.
Respiratory-Related Disorders – Cost Studies
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POLLEN ALLERGIC RHINITIS
Westerhout KY1, Verheggen BG1, Schreder CH2, Doering C2, Augustin M3
1Pharmerit International, Rotterdam, The Netherlands, 2Stallergenes GmbH, Kamp-Lintfort,
Germany, 3University Clinics of Hamburg, Hamburg, Germany
OBJECTIVES: A budget impact analysis was conducted to estimate the impact of
Oralair
®
on a market of selected number of relevant grass allergens. METHODS: In
this analysis the hypothetical market for grass allergens consisted of those com-
pounds for which efficacy data of comparable high-quality evidence have been
published. These compounds were Oralair®, Grazax® and ALK Depot SQ®. Actual
German market data from 2008-2010 served as a basis for future estimates of mar-
ket share development. Future predictions were made on market uptake and mar-
ket dynamics (i.e. which drug increases their market share at the expense of an-
other drug). German drug acquisition costs were taken from the Lauer-Taxe;
average annual treatment related costs have been extracted from a supportive
cost-effectiveness analysis. The analysis perspective was that of the German Stat-
utory Health insurance (SHI). Three scenario analyses were conducted over a
5-year time horizon. RESULTS: The total market budget in 2010 for these 3 thera-
pies was estimated at €48,209,211. The budget decreased with €7,049,756 over a
5-year period in the first scenario, when the annual uptake of Oralair® was set at
5% with market dynamics of 10%/90% (Grazax®/ ALK Depot SQ®). These savings
represent 2.9% of the total cumulative reference budget varying from 1.0% in 2011
to 4.8% in 2015. In the second scenario market uptake for Oralair® was varied from
2% to 6% annually. Accordingly, the budget was reduced by €2,819,902 to
€8,549,707. In the final scenario, shifting market dynamics from 0%/100% to 20%/
80% (Grazax®/ ALK Depot SQ®) showed a reduction of €5,389,170 to €8,710,342.
CONCLUSIONS: In all scenarios, an increase of Oralair’s® market share at the ex-
pense of Grazax® and ALK Depot SQ® was estimated to result in a decrease of the
budget varying from €2,819,902 to €8,710,342 over 5 years. This results in Oralair®
being a budget-saving treatment option.
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